Angiotech Pharmaceuticals, Inc.
ANGIOTECH PHARMACEUTICALS INC.
Angiotech Pharmaceuticals (NASDAQ:ANPI; TSX:ANP) is a world
leader in the emerging field of drug-coated medical devices and
biomaterials. We are pioneering the science of adding drugs to
medical devices and biomaterials to dramatically improve their
performance and solve some of medicines most vexing problems.
The Companys rapid growth is attributable to the discovery that
the antiproliferative drug, paclitaxel, could also block an
important cellular pathway involved in inflammation. Angiotechs
premier formulation of paclitaxel is a stent coating to prevent
restenosis in coronary arteries. Coronary stent sales presently
are US$2.3 billion annually, despite the fact that they fail in
approximately 25 to 50 percent of cases within six months. The
advent of the paclitaxel-eluting stent, which works over 600
percent better than the basic bare stent, has borne compelling
economic arguments and analysts now predict that the industry
will grow to US$5 billion or even as high as $14 billion
annually.
Angiotech is ready to take the same strategy from its drug-
eluting stent program to a whole new level to countless other
medical device and biomaterials that are placed in the human
body every year. These devices and biomaterials can be greatly
enhanced through co-administration of a drug (such as
paclitaxel) designed to improve the performance of the product.
Major medical device companies are now beginning to recognize
this technological shift. But Angiotech has been anticipating
and preparing for this shift for the past ten years and has
methodically built internal capabilities to lead the effort.
The Companys history began in 1992 with the efforts of its Co-
Founder and current president and CEO, William Hunter, MD, MSc,
to build the core technologies that serve as Angiotechs
foundation. Weve since grown to become one of the largest
pharmaceuticals companies in Canada, but well continually
strive to redefine and improve therapies in novel and innovative
ways to benefit patients worldwide.
Company Details
Year Established:
1992
Total Sales ($CDN):
$1,000,000 - $5,000,000
Number of Employees:
132
Company Information
Jeanne Bertonis
Title:
Chief Business Officer
Area of Responsibility:
Management Executive
Telephone:
(604) 221-7676
Fax:
(604) 221-2330
Email:
Click Here
David Mcmasters
Title:
VP, Intellectual Property & Corp Counsel
Telephone:
(604) 221-7676
Fax:
(604) 221-2330
Email:
Click Here
Cindy Yu
Title:
Corporate Communications Manager
Telephone:
(604) 221-7676
Fax:
(604) 221-2330
Email:
Click Here
Rui Avelar
Title:
Vice President, Investor Relations
Area of Responsibility:
Management Executive
Telephone:
(604) 221-7676
Fax:
(604) 221-2330
Email:
Click Here
George Daniloff
Title:
General Manager & VP, R&D
Area of Responsibility:
Management Executive
Telephone:
(604) 221-7676
Fax:
(604) 221-2330
Email:
Click Here
Ross Erickson
Title:
Vice President, Operations
Area of Responsibility:
Manufacturing/Production/Operations
Telephone:
(604) 221-7676
Fax:
(604) 221-2330
Email:
Click Here
William L. Hunter, Md
Title:
President and CEO
Area of Responsibility:
Management Executive
Telephone:
(604) 221-7676
Fax:
(604) 221-2330
Email:
Click Here
David Hall
Title:
Chief Financial Officer
Area of Responsibility:
Finance/Accounting
Telephone:
(604) 221-7676
Fax:
(604) 221-2330
Email:
Click Here
Products
Paclitaxel Stent Coatings
Paclitaxel Pastes
Paclitaxel Pastes
- Surgical adhesions
- Cancer
Status : Preclinical testing
Paclitaxel Films
Polymer films containg paclitaxel
vascular graft
Status : Preclinical testing
Paclitaxel Gels And Creams
Topical Gels and Creams containing paclitaxel
Psoriasis
Status : Phase I clinical testing
Paxceed
Micellar Paclitaxel for Rheumatoid Arthritis and Severe Psoriasis
Coseal
Costasis
Adhibit
Services
Drug-loaded Biomaterials
Biotechnology